Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04618393 · ClinicalTrials.gov registry record · Phase 1
A Study of EMB-02 in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by Shanghai EpimAb Biotherapeutics Co..
- Terminated
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT04618393: Clinical Trial Phase 1 study, sponsored by Shanghai EpimAb Biotherapeutics Co..
NCT04618393 is a Phase 1 study that was terminated before completion, run by Shanghai EpimAb Biotherapeutics Co.. The registered enrollment target is 47 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (22% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04618393, a Phase 1 study, was terminated before completion, sponsored by Shanghai EpimAb Biotherapeutics Co..
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
The primary purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for EMB-02 and to characterize the safety and tolerability of EMB-02 at the RP2Ds. Pharmacokinetics (PK), immunogenicity, and the anti-tumor activity of EMB-02 will also be assessed.
Primary Outcome
Incidence and severity of AE.
Interventions
- BIOLOGICAL EMB-02
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2021-03-11 |
| Est. Completion | 2024-03-21 |
| Phase | Phase 1 |
Why NCT04618393 stopped before completion
NCT04618393 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (22% lower).
The record links to 0 conditions, and to 1 intervention - of which EMB-02 is the first listed.
NCT04618393 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04618393 about?
NCT04618393 is a clinical study titled "A Study of EMB-02 in Participants With Advanced Solid Tumors". The primary purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for EMB-02 and to characterize the safety and tolerability of EMB-02 at the RP2Ds. Pharmacokinetics (PK), immunogenicity, and the anti-tumor activity of EMB-02 will also be asses...
What is the current status of trial NCT04618393?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2021-03-11. Estimated completion is 2024-03-21.
What interventions are being tested in trial NCT04618393?
The interventions under investigation include: EMB-02 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04618393?
This trial is sponsored by Shanghai EpimAb Biotherapeutics Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04618393's enrollment target sits among peer trials
47 1053rd of 2000 higher than 943 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI